• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用针对奥密克戎的mRNA疫苗或既往的新冠病毒疫苗进行加强免疫可引发针对奥密克戎变异株的特异性免疫反应。

Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.

作者信息

Wu Yi, Jia Xiaoying, Wu Namei, Zhang Xinghai, Wu Yan, Liu Yang, Zhou Minmin, Shen Yanqiong, Li Entao, Wang Wei, Lan Jiaming, Wang Yucai, Chiu Sandra

机构信息

Department of Laboratory Medicine, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, China.

School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230027, China.

出版信息

Acta Pharm Sin B. 2025 Feb;15(2):947-962. doi: 10.1016/j.apsb.2024.12.030. Epub 2024 Dec 30.

DOI:10.1016/j.apsb.2024.12.030
PMID:40177579
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11959960/
Abstract

Booster vaccinations are highly recommended in combating the SARS-CoV-2 Omicron variant and its subvariants. However, the optimal booster vaccination strategies and related immune mechanisms with different prior vaccinations are under-revealed. In this study, we systematically evaluated the immune responses in mice and hamsters with different prime-boost regimens before their protective efficacies against Omicron were detected. We found that boosting with Ad5-nCoV, S-2P or S-6P induced significantly higher levels of neutralization activities against Omicron variants than CoronaVac and ZF2001 by eliciting stronger germinal center (GC) responses. Specifically, S-6P induced even stronger antibody responses against Omicron variants in CoronaVac and Ad5-nCoV-primed animals than non-Omicron-specific vaccines but with limited differences as compared to Ad5-nCoV and S-2P. In addition, boosting with a specific vaccine has the potential to remodel the existing immune profiles. These findings indicated that adenovirus-vectored vaccines and mRNA vaccines would be more effective than other types of vaccines as booster shots in combating Omicron infections. Moreover, the protective efficacies of the vaccines in booster vaccinations are highly related to GC reactions in secondary lymphatic organs. In summary, these findings provide timely important information on prime-boost regimens and future vaccine design.

摘要

强烈建议接种加强针以对抗新冠病毒奥密克戎变种及其亚变种。然而,针对不同既往接种情况的最佳加强针接种策略及相关免疫机制尚未完全明确。在本研究中,我们在检测小鼠和仓鼠针对奥密克戎的保护效力之前,系统评估了它们在不同初免 - 加强免疫方案下的免疫反应。我们发现,与科兴疫苗(CoronaVac)和重组蛋白疫苗(ZF2001)相比,用腺病毒载体新冠疫苗(Ad5 - nCoV)、S - 2P或S - 6P加强免疫可通过引发更强的生发中心(GC)反应,诱导出显著更高水平的针对奥密克戎变种的中和活性。具体而言,在科兴疫苗和腺病毒载体新冠疫苗初免的动物中,S - 6P诱导出的针对奥密克戎变种的抗体反应甚至比非奥密克戎特异性疫苗更强,但与腺病毒载体新冠疫苗和S - 2P相比差异有限。此外,用特定疫苗加强免疫有重塑现有免疫图谱的潜力。这些发现表明,在对抗奥密克戎感染时,腺病毒载体疫苗和mRNA疫苗作为加强针比其他类型的疫苗更有效。此外,疫苗在加强针接种中的保护效力与次级淋巴器官中的GC反应高度相关。总之,这些发现为初免 - 加强免疫方案及未来疫苗设计提供了及时且重要的信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/cd3a43a38e62/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/0412a64c458c/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/a037cca2f0d9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/84ed7e7f9521/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/274cc54d45d0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/eb08d85fc7b1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/8eb1c4729541/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/5854e9453765/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/67467dd099d8/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/cd3a43a38e62/gr8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/0412a64c458c/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/a037cca2f0d9/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/84ed7e7f9521/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/274cc54d45d0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/eb08d85fc7b1/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/8eb1c4729541/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/5854e9453765/gr6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/67467dd099d8/gr7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c18c/11959960/cd3a43a38e62/gr8.jpg

相似文献

1
Boosting with Omicron-specific mRNA vaccine or historical SARS-CoV-2 vaccines elicits discriminating immune responses against Omicron variants.使用针对奥密克戎的mRNA疫苗或既往的新冠病毒疫苗进行加强免疫可引发针对奥密克戎变异株的特异性免疫反应。
Acta Pharm Sin B. 2025 Feb;15(2):947-962. doi: 10.1016/j.apsb.2024.12.030. Epub 2024 Dec 30.
2
Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model.腺病毒载体二价疫苗在小鼠模型中对野生型 SARS-CoV-2 和奥密克戎变异株的免疫原性。
Vaccine. 2024 Feb 27;42(6):1292-1299. doi: 10.1016/j.vaccine.2024.01.073. Epub 2024 Jan 30.
3
Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial.在中国,两剂科兴新冠疫苗后接种一剂mRNA和三种平台型新冠疫苗作为第三剂的免疫原性、持久性和安全性:一项随机、双盲、安慰剂对照的2期试验。
EClinicalMedicine. 2022 Sep 28;54:101680. doi: 10.1016/j.eclinm.2022.101680. eCollection 2022 Dec.
4
Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection.与注射用和雾化用 Ad5-nCoV 加强针和 BA.2 感染相关的中和抗体水平。
BMC Med. 2023 Jul 3;21(1):233. doi: 10.1186/s12916-023-02942-3.
5
SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.SARS-CoV-2 S1 亚单位加强疫苗在老年小鼠中引发强烈的体液免疫应答。
Microbiol Spectr. 2023 Jun 15;11(3):e0436322. doi: 10.1128/spectrum.04363-22. Epub 2023 May 10.
6
Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.两剂蛋白亚单位疫苗 MVC-COV1901 初免后加强接种多剂 mRNA 疫苗可增强针对新型 SARS-CoV-2 变异株的体液和细胞免疫应答。
Microbiol Spectr. 2022 Oct 26;10(5):e0060922. doi: 10.1128/spectrum.00609-22. Epub 2022 Aug 25.
7
Boosting with an aerosolized Ad5-nCoV elicited robust immune responses in inactivated COVID-19 vaccines recipients.雾化 Ad5-nCoV 增强免疫在新冠灭活疫苗接种者中引发了强烈的免疫反应。
Front Immunol. 2023 Oct 4;14:1239179. doi: 10.3389/fimmu.2023.1239179. eCollection 2023.
8
Safety, immunogenicity, and efficacy of an mRNA COVID-19 vaccine (RQ3013) given as the fourth booster following three doses of inactivated vaccines: a double-blinded, randomised, controlled, phase 3b trial.在三剂灭活疫苗后作为第四剂加强针接种的mRNA新冠疫苗(RQ3013)的安全性、免疫原性和有效性:一项双盲、随机、对照的3b期试验。
EClinicalMedicine. 2023 Sep 21;64:102231. doi: 10.1016/j.eclinm.2023.102231. eCollection 2023 Oct.
9
Second Boost of Omicron SARS-CoV-2 S1 Subunit Vaccine Induced Broad Humoral Immune Responses in Elderly Mice.新型冠状病毒奥密克戎变异株S1亚基疫苗的第二次加强免疫在老年小鼠中诱导了广泛的体液免疫反应。
bioRxiv. 2024 Feb 6:2024.02.05.578925. doi: 10.1101/2024.02.05.578925.
10
Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.成年人接种同源和异源加强疫苗后的免疫反应和转录谱。
Front Immunol. 2024 Sep 12;15:1461419. doi: 10.3389/fimmu.2024.1461419. eCollection 2024.

引用本文的文献

1
Transforming beef quality through healthy breeding: a strategy to reduce carcinogenic compounds and enhance human health: a review.通过健康养殖改善牛肉品质:减少致癌化合物并促进人类健康的策略:综述
Mamm Genome. 2025 May 9. doi: 10.1007/s00335-025-10129-9.

本文引用的文献

1
Long-term immune response to Omicron-specific mRNA vaccination in mice, hamsters, and nonhuman primates.小鼠、仓鼠和非人灵长类动物对奥密克戎特异性mRNA疫苗的长期免疫反应。
MedComm (2020). 2023 Dec 15;4(6):e460. doi: 10.1002/mco2.460. eCollection 2023 Dec.
2
SARS-CoV-2 variant biology: immune escape, transmission and fitness.SARS-CoV-2 变体生物学:免疫逃逸、传播和适应性。
Nat Rev Microbiol. 2023 Mar;21(3):162-177. doi: 10.1038/s41579-022-00841-7. Epub 2023 Jan 18.
3
Omicron variant: a booster depending on infection histories.
奥密克戎变种:根据感染史接种加强针。
Signal Transduct Target Ther. 2023 Jan 4;8(1):6. doi: 10.1038/s41392-022-01279-2.
4
Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB.奥密克戎亚变体BQ.1.1和XBB的体液免疫逃逸
Lancet Infect Dis. 2023 Jan;23(1):30-32. doi: 10.1016/S1473-3099(22)00816-7. Epub 2022 Dec 7.
5
Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation.混合免疫和二价加强疫苗接种对奥密克戎亚谱系中和作用的影响。
Lancet Infect Dis. 2023 Jan;23(1):25-28. doi: 10.1016/S1473-3099(22)00792-7. Epub 2022 Dec 5.
6
Acute and postacute sequelae associated with SARS-CoV-2 reinfection.与 SARS-CoV-2 再感染相关的急性和后期后遗症。
Nat Med. 2022 Nov;28(11):2398-2405. doi: 10.1038/s41591-022-02051-3. Epub 2022 Nov 10.
7
Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.二价 SARS-CoV-2 mRNA 疫苗提高中和广度并预防小鼠感染奥密克戎变异株 BA.5。
Nat Med. 2023 Jan;29(1):247-257. doi: 10.1038/s41591-022-02092-8. Epub 2022 Oct 20.
8
Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5.奥密克戎 BA.2 突破感染增强了对 BA.2.12.1 和 BA.4/BA.5 的交叉中和作用。
Sci Immunol. 2022 Nov 25;7(77):eade2283. doi: 10.1126/sciimmunol.ade2283. Epub 2022 Nov 18.
9
Omicron SARS-CoV-2 mutations stabilize spike up-RBD conformation and lead to a non-RBM-binding monoclonal antibody escape.奥密克戎 SARS-CoV-2 突变稳定了刺突上 RBD 的构象,导致非 RBM 结合的单克隆抗体逃逸。
Nat Commun. 2022 Aug 24;13(1):4958. doi: 10.1038/s41467-022-32665-7.
10
SARS-CoV-2 prefusion spike protein stabilized by six rather than two prolines is more potent for inducing antibodies that neutralize viral variants of concern.SARS-CoV-2 三聚体前融合刺突蛋白由六个脯氨酸稳定而非两个脯氨酸稳定时,更能诱导中和相关病毒变异株的抗体。
Proc Natl Acad Sci U S A. 2022 Aug 30;119(35):e2110105119. doi: 10.1073/pnas.2110105119. Epub 2022 Aug 22.